Treatment Preference Research in Alzheimer ’s Disease

Community and Patient Preference Research (CaPPRe), an independent research organisation, is working on behalf of pharmaceutical company Novo Nordisk to conduct research with people diagnosed with early-stage Alzheimer’s Disease.

The study involves an online survey with people diagnosed with early-stage Alzheimer’s disease, carers of those with early-stage Alzheimer’s disease, and physicians who manage and treat this condition. It aims to understand what people value from Alzheimer’s disease medications and how people decide between different medication options. 

We aim to publish the results in an academic journal where the evidence can be used to advocate for better treatments. 

We are looking for people living with Alzheimer's disease and people currently caring for someone diagnosed with early-stage Alzheimer's Disease to participate.

Inclusion criteria
Person living with early-stage Alzheimer's Disease:
• 18 years and over 
• Australian citizen or permanent resident 
• Diagnosed by a doctor as having early-stage Alzheimer’s Disease 

Person caring for someone living with early-stage Alzheimer's Disease 
• 18 years and over
• Currently caring for someone diagnosed with early-stage Alzheimer’s Disease  

Exclusion criteria
• Participants who work for a pharmaceutical or medical devices company;
• Participants without access to the Internet;
• Participants not able to read and understand English without the need of a translator;
• People who have been diagnosed as having moderate or severe Alzheimer’s Disease;
• Carers who are caring for someone who has been diagnosed as having moderate or severe Alzheimer’s Disease. 

Participation involves completing an online survey which will take about 20 minutes. In the online survey, participants will be shown several 'scenarios' for different hypothetical Alzheimer's Disease medications and asked to choose which medication option they personally prefer. 

Participants will also be asked for other information about the impact of the condition on their (or the person they care for's) health and life, experiences with the medication they have received (or the person they care for has received), and other information about themselves such as the postcode they live in. 

Please note that the survey must be completed on a laptop/desktop or iPad - the main part of the survey includes a treatment choice task which is not mobile-phone friendly.